Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Mesenchymal Stem Cells
100%
Preeclampsia
100%
Senescence
100%
Angiogenic Potential
100%
Adipose-derived Mesenchymal Stem Cells (ADMSCs)
100%
Monocyte Chemoattractant protein-1 (MCP-1)
26%
Dasatinib
26%
Senescence-associated Secretory Phenotype
26%
Angiogenesis
20%
Tumor Necrosis Factor-α
20%
Gene Expression
13%
Interleukin-6
13%
β-Galactosidase (β-Gal)
13%
Senolytics
13%
Inhibitory Effect
13%
Subcutaneous Adipose Tissue
13%
Senescence Markers
13%
Normotensive Pregnancy
13%
Senescence-associated
13%
Impaired Angiogenesis
13%
Live Cell Analysis
6%
Inflammation
6%
Interleukin-8
6%
Quantitative PCR
6%
Cell-to-cell
6%
Apoptosis
6%
Systemic Inflammation
6%
Inflammatory Response
6%
Plasminogen Activator inhibitor-1 (PAI-1)
6%
Multipotent Cells
6%
Cesarean Section (C-section)
6%
Tissue Explants
6%
In Vivo Exposure
6%
Angiogenic Activity
6%
Senescent Phenotype
6%
Hypertensive Disorders
6%
Stem Cell Aging
6%
IncuCyte
6%
Abdominal Fat Tissue
6%
Mechanism-based Therapy
6%
Medicine and Dentistry
Mesenchymal Stem Cell
100%
Pre-Eclampsia
100%
Adipose-Derived Mesenchymal Stem Cell
100%
Angiogenesis
33%
Monocyte Chemotactic Protein 1
26%
Dasatinib
26%
Tumor Necrosis Factor
20%
Adipose Tissue
13%
Gene Expression
13%
Upregulation
13%
P16
13%
Inflammation
13%
Interleukin 6
13%
Senescence-Associated Beta-Galactosidase
13%
In Vitro
6%
Serositis
6%
Programmed Cell Death
6%
Real-Time Polymerase Chain Reaction
6%
P21
6%
Abdominal Fat
6%
Cellular Senescence
6%
Plasminogen Activator Inhibitor-1
6%
Diseases
6%
Fat Tissue
6%
Immunology and Microbiology
Adipose Tissue
100%
Mesenchymal Stem Cell
100%
Angiogenesis
31%
Monocyte Chemotactic Protein 1
25%
Staining
25%
Tumor Necrosis Factor Alpha
18%
Gene Expression
12%
Upregulation
12%
Interleukin 6
12%
Beta-Galactosidase
12%
Inflammation
6%
Systemic Inflammation
6%
Explant
6%
Real-Time Polymerase Chain Reaction
6%
Inflammation Response
6%
Tissue Section
6%
Abdominal Fat
6%
Interleukin 8
6%
Programmed Cell Death
6%
In Vitro
6%